AmineDB: Large scale docking of amines with CYP2D6 and scoring for druglike properties—towards defining the scope of the chemical defense against foreign amines in humans

References

• Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metabolism and Disposition 2003; 31: 289–293
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. British Journal of Clinical Pharmacology 2002; 53: 111–122
   PubMed Web of Science ®Google Scholar
• Bezeley P, Prithivi S, Struble CA, Povinelli R, Sem DS. Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: Predicting affinity and conformational sampling. Journal of Chemical Information and Modeling 2006; 46: 2698–2708
   PubMed Web of Science ®Google Scholar
• Casabianca LB, de Dios AC. Relationship between NMR shielding and heme binding strength for a series of 7-substituted quinolines. Journal of Physical Chemistry A 2006; 110: 7787–7792
   PubMed Web of Science ®Google Scholar
• Cohen LH, Remley MJ, Raunig D, Vaz ADN. In Vitro drug interactions of Cytochrome P450: An evaluation of fluorogenic to conventional substrates. Drug Metabolism and Disposition 2003; 31: 1005–1015
   PubMed Web of Science ®Google Scholar
• de Graaf C, Oostenbrink C, Keizers PH, van der Wijst T, Jongejan A, Vermeulen NP. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. Journal of Medicinal Chemistry 2006; 49: 2417–2430
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6. Journal of Medicinal Chemistry 1999a; 42: 1515–1524
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. Journal of Medicinal Chemistry 1999b; 42: 4062–4070
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Bijloo GJ, Martens BJ, van Acker FA, Vermeulen NP. A refined substrate model for human cytochrome P450 2D6. Chemical Research in Toxicology 1997; 10: 41–48
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Vermeulen NP, Kramer JD, van Acker FA, Donne-Op den Kelder GM. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. Chemical Research in Toxicology 1996; 9: 1079–1091
   PubMed Web of Science ®Google Scholar
• Dewar MJS, Hashmall JA, Venier CG. Ground states of conjugated molecules. IX. Hydrocarbon radicals and radical ions. Journal of the American Chemical Society 1968; 90: 1953–1957
   Web of Science ®Google Scholar
• Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. AM1: A new general purpose quantum mechanical molecular model. Journal of the American Chemical Society 1985; 107: 3902–3909
   Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999; 9: 477–489
   PubMedGoogle Scholar
• Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. Journal of Computer-aided Molecular Design 1997; 11: 425–445
   PubMed Web of Science ®Google Scholar
• Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, Lennard MS, Tucker GT, et al. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. Journal of Biological Chemistry 1995; 270: 29055–29058
   PubMed Web of Science ®Google Scholar
• Flanagan JU, Marechal JD, Ward R, Kemp CA, McLaughlin LA, Sutcliffe MJ, Roberts GC, Paine MJ, Wolf CR. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: Mutation leads to the formation of a novel dextromethorphan metabolite. Biochemical Journal 2004; 380: 353–360
   PubMed Web of Science ®Google Scholar
• Ghose AK, Viswanadhan VN, Wendoloski JJ. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragment methods: An analysis of AlogP and ClogP methods. Journal of Physical Chemistry A 1998; 102: 3762–3772
   Web of Science ®Google Scholar
• Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, et al. Diversity in the oxidation of substrates by cytochrome P450 2D6: Lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 2002; 41: 11025–11034
   PubMed Web of Science ®Google Scholar
• Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modelling. Electrophoresis 1997; 18: 2714–2723
   PubMed Web of Science ®Google Scholar
• Hassan M, Brown RD, Varma-O’Brien Rogers D. Cheminformatics analysis and learning in a data pipelining environment. Molecular Diversity 2006; 10: 283–299
   PubMed Web of Science ®Google Scholar
• Hayhurst GP, Harlow J, Chowdry J, Gross E, Hilton E, Lennard MS, Tucker GT, Ellis SW. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochemical Journal 2001; 355: 373–379
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK. ZINC—a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 2005; 45: 177–182
   PubMed Web of Science ®Google Scholar
• Islam SA, Wolf CR, Lennard MS, Sternberg MJ. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991; 12: 2211–2219
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology 1997; 267: 727–748
   PubMed Web of Science ®Google Scholar
• Keizers PH, de Graaf C, de Kanter FJ, Oostenbrink C, Feenstra KA, Commandeur JN, Vermeulen NP. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: In silico predictions and experimental validation. Journal of Medicinal Chemistry 2005; 48: 6117–6127
   PubMed Web of Science ®Google Scholar
• Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ. Validation of model of cytochrome P450 2D6: An in silico tool for predicting metabolism and inhibition. Journal of Medicinal Chemistry 2004; 47: 5340–5346
   PubMed Web of Science ®Google Scholar
• Kirton SB, Kemp CA, Tomkinson NP, St-Gallay S, Sutcliffe MJ. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 2002; 49: 216–231
   PubMed Web of Science ®Google Scholar
• Koymans LM, Vermeulen NP, Baarslag A, Donne-Op den Kelder GM. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. Journal of Computer-aided Molecular Design 1993; 7: 281–289
   PubMed Web of Science ®Google Scholar
• Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, Donne-Op den Kelder GM. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chemical Research in Toxicology 1992; 5: 211–219
   PubMed Web of Science ®Google Scholar
• Leed A, DuBay K, Ursos LM, Sears D, De Dios AC, Roepe PD. Solution structures of antimalarial drug-heme complexes. Biochemistry 2002; 41: 10245–10255
   PubMed Web of Science ®Google Scholar
• Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GC, Aronoff GR. Fluoxetine: Clinical pharmacology and physiologic disposition. Journal of Clinical Psychiatry 1985; 46: 14–19
   PubMed Web of Science ®Google Scholar
• Lewis DFV. Guide to cytochromes P450 structure and function. Taylor & Francis, New York 2001
   Google Scholar
• Lewis DFV. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Current Medicinal Chemistry 2003; 10: 1955–1972
   PubMed Web of Science ®Google Scholar
• Lewis DF, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997; 27: 319–339
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 2001; 46: 1–26
   Web of Science ®Google Scholar
• Lussenburg BM, Keizers PH, de Graaf C, Hidestrand M, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochemical Pharmacology 2005; 70: 1253–1261
   PubMed Web of Science ®Google Scholar
• McLaughlin LA, Paine MJ, Kemp CA, Marechal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, Wolf CR. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. Journal of Biological Chemistry 2005; 280: 38617–38624
   PubMed Web of Science ®Google Scholar
• Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1996; 16: 449–464
   Web of Science ®Google Scholar
• Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112
   PubMed Web of Science ®Google Scholar
• Modi S, Paine MJ, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR, Roberts GC. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996; 35: 4540–4550
   PubMed Web of Science ®Google Scholar
• Morgan HL. The generation of a unique machine description for chemical structures—A technique developed at Chemical Abstract Service. Journal of Chemical Documentation 1965; 2: 107–113
   Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. Journal of Computational Chemistry 1998; 19: 1639–1662
   Web of Science ®Google Scholar
• Mortimer O, Persson K, Ladona MG, Spalding D, Zanger UM, Meyer UA, Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P-450IID1. Clinical Pharmacology and Therapeutics 1990; 47: 27–35
   PubMed Web of Science ®Google Scholar
• Olah MM, Bologa CG, Oprea TI. Strategies for compound selection. Current Drug Discovery Technologies 2004; 1: 211–220
   PubMedGoogle Scholar
• Ortiz de Montellano P. Structure, function and biochemistry3rd. Plenum Press, New York 2005
   Google Scholar
• Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, Wolf CR. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. Journal of Biological Chemistry 2003; 278: 4021–4027
   PubMed Web of Science ®Google Scholar
• Peitsch MC. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochemical Society Transactions 1996; 24: 274–279
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. Crystal structure of human cytochrome P450 2D6. Journal of Biological Chemistry 2006; 281: 7614–7622
   PubMed Web of Science ®Google Scholar
• Sadowski J. 3D structure generation. Handbook of chemoinformatics—from data to knowledge, J Gasteiger. Wiley-VCH, Weinheim 2004
   Google Scholar
• Sadowski J, Gasteiger J. From atoms and bonds to three-dimensional atomic coordinates: Automatic model builders. Chemical Reviews 1993; 93: 2567–2581
   Web of Science ®Google Scholar
• Schenkman JB, Sligar SG, Cinti DL. Substrate interaction with cytochrome P-450. Pharmacology and Therapeutics 1981; 12: 43–71
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. Journal of Biological Chemistry 2004; 279: 9497–9503
   PubMed Web of Science ®Google Scholar
• Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Research 2003; 31: 3381–3385
   PubMed Web of Science ®Google Scholar
• Slaughter RL, Edwards DJ. Recent advances: The cytochrome P450 enzymes. Annals of Pharmacotherapy 1995; 29: 619–624
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology 2002; 22: 419–423
   PubMed Web of Science ®Google Scholar
• Strausberg RL, Schreiber SL. From knowing to controlling: A path from genomics to drugs using small molecule probes. Science 2003; 300: 294–295
   PubMed Web of Science ®Google Scholar
• Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats for in vitro drug metabolism assays using Vivid® fluorescent substrates and recombinant human cytochrome P450 enzymes. Journal of Biomolecular Screening 2005; 10: 55–66
   Google Scholar
• Venhorst J, Onderwater RC, Meerman JH, Commandeur JN, Vermeulen NP. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Drug Metabolism and Disposition 2000; 28: 1524–1532
   PubMed Web of Science ®Google Scholar
• Venhorst J, ter Laak AM, Commandeur JN, Funae Y, Hiroi T, Vermeulen NP. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. Journal of Medicinal Chemistry 2003; 46: 74–86
   PubMed Web of Science ®Google Scholar
• Walsh P. Physician's desk reference. Medical Economics and Thomson Healthcare, New Jersey 2003, (Editor)
   Google Scholar
• Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. Journal of Computer-aided Molecular Design 2002; 16: 11–26
   PubMed Web of Science ®Google Scholar
• Wang R, Lu Y, Wang S. Comparative evaluation of 11 scoring functions for molecular docking. Journal of Medicinal Chemistry 2003; 46: 2287–2303
   PubMed Web of Science ®Google Scholar
• Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. Journal of Biological Chemistry 2004; 279: 35630–35637
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464–468
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305: 683–686
   PubMed Web of Science ®Google Scholar
• Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Research 1985; 45: 2116–2122
   PubMed Web of Science ®Google Scholar
• Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. Journal of Medicinal Chemistry 2004; 47: 4463–4470
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. Journal of Biological Chemistry 2004; 279: 38091–38094
   PubMed Web of Science ®Google Scholar
• Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nature Structural and Molecular Biology 2005; 12: 822–823
   PubMed Web of Science ®Google Scholar
• Yao H, Costache AD, Sem DS. Chemical proteomic tool for ligand mapping of CYP anti-targets: An NMR-compatible 3D QSAR descriptor in the heme-based coordinate system. Journal of Chemical Information and Computer Science 2004; 44: 1456–1465
   PubMedGoogle Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Archives of Pharmacology 2004; 369: 23–37
   PubMed Web of Science ®Google Scholar